Voyager Therapeutics, Inc.
VYGRHealthcare|Biotechnology|US
$1.86
+0.14 (+8.43%)
Tangible Book / Share
$2.19
Cash / Share
$1.73
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06874621 VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease | Alzheimer's Disease (AD) | P1P2 | Active | 52 | RCT, Double-blind | VY7523, Placebo Comparator |
| NCT07764146 An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease | Alzheimer s Disease | P1 | Recruiting | 18 | Open-label | VY1706 Low dose, VY1706 Mid dose, VY1706 High Dose |
| NCT05490225 Access Cannulation Trial II | Dialysis; Complications, Vascular Access Complication | N/A | Recruiting | 100 | Open-label | — |
| NCT00231946 ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301) | Alzheimer's Disease | P3 | Completed | 555 | RCT, Double-blind | VP4896 |
| NCT00063310 ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation | Alzheimer Disease | P2 | Completed | 90 | RCT, Double-blind | Leuprolide acetate |
| NCT00076440 Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study | Alzheimer Disease | P2 | Completed | 90 | RCT, Double-blind | Leuprolide acetate |
| NCT01973543 Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease | Parkinson's Disease | P1 | Completed | 15 | Single-blind | VY-AADC01 |
| NCT03065192 Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease | Idiopathic Parkinson's Disease, Parkinson's Disease | P1 | Completed | 16 | Open-label | VY-AADC01 |
| NCT04885114 Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease | Huntington Disease | P1 | Withdrawn | — | RCT, Open-label | — |
| NCT03562494 VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1) | Parkinson's Disease | P1 | Completed | 14 | RCT, Double-blind | VY-AADC02 |
| NCT03733496 Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies | Parkinson's Disease | Completed | 14 | — | — |